Osteoporosis International最新文献

{"title":"Correction: determination of the combined effects of asian herbal medicine with calcium and/or vitamin D supplements on bone mineral density in primary osteoporosis: a systematic review and meta-analysis.","authors":"Hee-Joo Park, Min-Gyeong Kim, Young-Seo Yoo, Boram Lee, Yu-Jin Choi, Chang-Gue Son, Eun-Jung Lee","doi":"10.1007/s00198-024-07335-7","DOIUrl":"10.1007/s00198-024-07335-7","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"577"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142837950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel hybrid deep learning framework based on biplanar X-ray radiography images for bone density prediction and classification.","authors":"Kun Zhou, Yuqi Zhu, Xiao Luo, Shan Yang, Enhui Xin, Yanwei Zeng, Junyan Fu, Zhuoying Ruan, Rong Wang, Liqin Yang, Daoying Geng","doi":"10.1007/s00198-024-07378-w","DOIUrl":"10.1007/s00198-024-07378-w","url":null,"abstract":"<p><p>This study utilized deep learning for bone mineral density (BMD) prediction and classification using biplanar X-ray radiography (BPX) images from Huashan Hospital Medical Checkup Center. Results showed high accuracy and strong correlation with quantitative computed tomography (QCT) results. The proposed models offer potential for screening patients at a high risk of osteoporosis and reducing unnecessary radiation and costs.</p><p><strong>Purpose: </strong>To explore the feasibility of using a hybrid deep learning framework (HDLF) to establish a model for BMD prediction and classification based on BPX images. This study aimed to establish an automated tool for screening patients at a high risk of osteoporosis.</p><p><strong>Methods: </strong>A total of 906 BPX scans from 453 subjects were included in this study, with QCT results serving as the reference standard. The training-validation set:independent test set ratio was 4:1. The L1-L3 vertebral bodies were manually annotated by experienced radiologists, and the HDLF was established to predict BMD and diagnose abnormality based on BPX images and clinical information. The performance metrics of the models were calculated and evaluated.</p><p><strong>Results: </strong>The <math> <msup><mrow><mi>R</mi></mrow> <mn>2</mn></msup> </math> values of the BMD prediction regression model in the independent test set based on BPX images and multimodal data (BPX images and clinical information) were 0.77 and 0.79, respectively. The Pearson correlation coefficients were 0.88 and 0.89, respectively, with P-values < 0.001. Bland-Altman analysis revealed no significant difference between the predictions of the models and QCT results. The classification model achieved the highest AUC of 0.97 based on multimodal data in the independent test set, with an accuracy of 0.93, sensitivity of 0.84, specificity of 0.96, and F1 score of 0.93.</p><p><strong>Conclusion: </strong>This study demonstrates that deep learning neural networks applied to BPX images can accurately predict BMD and perform classification diagnoses, which can reduce the radiation risk, economic consumption, and time consumption associated with specialized BMD measurement.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"521-530"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study.","authors":"Zhenna Huang, Tzu-Chi Liao, Albert Tzu-Ming Chuang, Shih-Chieh Shao, Jeff Lange, Tzu-Chieh Lin, Min Kim, Edward Chia-Cheng Lai","doi":"10.1007/s00198-024-07381-1","DOIUrl":"10.1007/s00198-024-07381-1","url":null,"abstract":"<p><p>Most subjects in osteoporosis clinical trials were women with postmenopausal osteoporosis and while bridging studies (BMD endpoint) provide an expectation that osteoporosis medications will reduce fracture risk in men. This real-world study shows direct evidence of fracture risk reduction among men with osteoporosis (36% of hip fracture reduction with denosumab).</p><p><strong>Purpose: </strong>Direct evidence for fracture risk reduction of medications used among men with osteoporosis is very limited. This study aims to evaluate the real-world effectiveness of denosumab in reducing fracture risk.</p><p><strong>Methods: </strong>This study included 13,797 men aged ≥ 50 years with osteoporosis who had initiated denosumab in Taiwan. Taiwan's National Health Insurance Research Database includes all Taiwan residents' complete health claim data. We compared incidence rates of clinical fractures between patients on denosumab 60 mg subcutaneously every 6 months (on-treatment) and patients ending therapy after one administration (off-treatment). Propensity score (PS) analysis, adjusting for measured differences at baseline covariates, was used to estimate the adjusted hazard ratio using a Cox proportion hazards model.</p><p><strong>Results: </strong>During follow-up, 248 hip fracture events occurred. The crude incidence rates of hip fracture were 1.13 events and 1.73 events per 100 person-years in on-treatment and off-treatment cohorts, respectively. After PS inverse probability of treatment weighting, the cohorts achieved balance in all 59 covariates. The hip fracture event rate was lower in on-treatment cohort versus off-treatment cohort by 36% (hazard ratio, 0.64 [95% CI 0.50-0.83]). A similar magnitude of risk reduction was observed in clinical vertebral and nonvertebral fractures. A series of sensitivity analysis, including a validation analysis using a-million individual health records, demonstrated that unmeasured confounders were not suggested to impact study result interpretation.</p><p><strong>Conclusion: </strong>In this large, real-world study evaluating denosumab treatment among men with osteoporosis, the observed fracture risk reductions were consistent with the available risk reductions demonstrated in clinical trials among women with postmenopausal osteoporosis.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"465-473"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fracture liaison service (FLS) is associated with lower subsequent fragility fracture risk and mortality: NoFRACT (the Norwegian capture the fracture initiative).","authors":"Camilla Andreasen, Cecilie Dahl, Frede Frihagen, Tove T Borgen, Trude Basso, Jan-Erik Gjertsen, Wender Figved, Torbjørn Wisløff, Gunhild Hagen, Ellen M Apalset, Jens M Stutzer, Ida Lund, Ann K Hansen, Frida I Nissen, Ragnar M Joakimsen, Unni Syversen, Erik F Eriksen, Lars Nordsletten, Tone K Omsland, Åshild Bjørnerem, Lene Bergendal Solberg","doi":"10.1007/s00198-024-07376-y","DOIUrl":"10.1007/s00198-024-07376-y","url":null,"abstract":"<p><p>Subsequent fracture rates and associated mortality were compared before and after the introduction of fracture liaison service (FLS). In 100,198 women and men, FLS was associated with 13% and 10% lower risk of subsequent fragility fractures and 18% and 15% lower mortality. The study suggests that FLS may prevent fractures.</p><p><strong>Purpose: </strong>Efficient fracture prevention strategies are warranted to control the global fracture burden. We investigated the effect of a standardized fracture liaison service (FLS) intervention on subsequent fracture risk and mortality.</p><p><strong>Methods: </strong>The NoFRACT study was designed as a multicenter, pragmatic, register-supported, stepped-wedge cluster-randomized trial. The FLS intervention was introduced in three clusters with 4-month intervals starting May 2015 through December 2018 and included evaluation of osteoporosis and treatment in patients over 50 years with a low-energy fracture. Based on data from the Norwegian Patient Registry, patients with index fractures were assigned to the control period (2011-2015) or intervention period (2015-2018) depending on the time of fracture. Rates of subsequent fragility fractures (distal forearm, proximal humerus, or hip) and all-cause mortality were calculated.</p><p><strong>Results: </strong>A total of 100,198 patients (mean age 69.6 years) suffered an index fracture of any type. During a maximum follow-up of 4.7 years, 11% (6948) of the women and 6% (2014) of the men experienced a subsequent fragility fracture, and 20% (14,324) of the women and 22% (8,326) of the men died. FLS was associated with 13% lower subsequent fragility fracture risk in women (hazard ratio (HR) 0.87, 95% confidence intervals (CI) 0.83-0.92) and 10% in men (HR 0.90, 95% CI 0.81-0.99) and 18% lower mortality in women (HR 0.82, 95% CI 0.79-0.86) and 15% in men (HR 0.85, 95% CI 0.81-0.89).</p><p><strong>Conclusion: </strong>A standardized FLS intervention was associated with a lower risk of subsequent fragility fractures and mortality and may contribute to reduce the global fracture burden.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"501-512"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time trend analysis of osteoporosis prevalence among adults 50 years of age and older in the USA, 2005-2018.","authors":"Chris M Naso, Shuo-Yu Lin, Ge Song, Hong Xue","doi":"10.1007/s00198-025-07395-3","DOIUrl":"10.1007/s00198-025-07395-3","url":null,"abstract":"<p><p>Using data from NHANES for years 2005-2018, we examined temporal trends in osteoporosis prevalence and the proportion of undiagnosed osteoporosis in the United States of America. Our results suggested statistically significant increases in osteoporosis prevalence across several demographic groups. These findings carry profound implications for public health, given increased life expectancy and burden of chronic diseases.</p><p><strong>Introduction: </strong>This is the first study to assess osteoporosis prevalence trends over time and the proportion of undiagnosed osteoporosis across gender, ethnicity/race, and age groups.</p><p><strong>Methods: </strong>Observational time trend analyses were conducted using the 2005-2006, 2007-2008, 2009-2010, 2013-2014, and 2017-2018 National Health and Nutrition Examination Survey (NHANES) datasets, along with a descriptive analysis using the 2017-2018 NHANES dataset to capture the proportion of undiagnosed osteoporosis.</p><p><strong>Results: </strong>The findings showed a statistically significant increase in osteoporosis prevalence among women, non-Hispanic Whites, and all age groups (except for individuals 80 years of age and older) during the study period. A subsequent analysis examining individuals by both gender and ethnicity/race demonstrated a statistically significant increase among Other Hispanic men and non-Hispanic White women. Additional descriptive analyses found that 69.12% of individuals with osteoporosis went undiagnosed. Specifically, 86.88% of men and 84.77% of individuals 50-59 years of age with osteoporosis went undiagnosed, representing the two highest groups.</p><p><strong>Discussion and conclusion: </strong>The substantial and increasing prevalence among certain groups and sub-groups, along with the lack of diagnostic capture of osteoporosis, highlights existing gaps in public health efforts and care delivery infrastructure. This paper highlights high-risk groups and sub-groups that may benefit most from accelerated initiatives to reduce the burden of illness associated with osteoporosis.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"547-554"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.","authors":"Toshitaka Yukishima, Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Shin-Ichiro Ohmura, Ken Nakata, Seiji Okada, Tomonori Kobayakawa","doi":"10.1007/s00198-025-07386-4","DOIUrl":"10.1007/s00198-025-07386-4","url":null,"abstract":"<p><p>This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers.</p><p><strong>Purpose: </strong>To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis.</p><p><strong>Methods: </strong>This retrospective, case-controlled, multicenter study included 389 patients who switched from BP to DMAb, TPTD, or ROMO due to treatment inefficacy. Propensity score matching was used to align patient backgrounds, resulting in 45 patients per group. Baseline characteristics included a mean age of 73.8 years, prior BP treatment duration of 37.1 months, and bone mineral density (BMD) T-scores of -2.8 in the lumbar spine (LS), -2.5 in the total hip (TH), and -2.7 in femoral neck (FN). BMD and bone turnover markers were assessed over 12 months.</p><p><strong>Results: </strong>Following the switch from BP, the ROMO group demonstrated a dual effect of decreased bone resorption and increased bone formation markers. The TPTD group exhibited the highest increases in both markers, while the DMAb group suppressed both. After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups. Additionally, the ROMO group showed greater increases in the TH (3.3%) than TPTD group (0.8%; p < 0.01). Only the ROMO group showed a significant BMD increase in the FN (2.0%; p < 0.01 from baseline).</p><p><strong>Conclusion: </strong>Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"531-538"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing emergency management for osteoporotic patients: a commentary on physical activity and mortality insights.","authors":"Zhongxing Liu, Mengzhe Tian, Lincheng Duan","doi":"10.1007/s00198-024-07371-3","DOIUrl":"10.1007/s00198-024-07371-3","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"561-562"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in screening and treatment of osteoporosis after periprosthetic fractures from 2010 to 2020.","authors":"Jackson W Durbin, Amy Y Zhao, Eric Cui, Amil R Agarwal, Andrew Smith, Alex Gu, Gregory J Golladay, Savyasachi C Thakkar","doi":"10.1007/s00198-025-07385-5","DOIUrl":"10.1007/s00198-025-07385-5","url":null,"abstract":"<p><p>Osteoporosis is often underrecognized and undertreated following periprosthetic fractures (PPF). Our study found that between 2010 and 2020, there has been no significant change in the rates of osteoporosis screening or treatment within 1 year following PPF. Orthopedic surgeons can play an integral role in helping to curtail the osteoporosis epidemic.</p><p><strong>Purpose: </strong>Periprosthetic fractures (PPF) typically occur from low-energy mechanisms and are pathognomonic for osteoporosis. However, osteoporosis is often underrecognized and undertreated. The aim of this study was to examine trends in dual energy X-ray absorptiometry (DXA) scans and treatment of osteoporosis after PPF between 2010 and 2020.</p><p><strong>Methods: </strong>Patients older than 40 who experienced a lower extremity PPF between 2010 and 2020 and had no prior history of osteoporosis screening or treatment were identified utilizing a large national administrative database. Rates of bone mineral density (BMD) measurement using DXA and anti-osteoporotic treatment with pharmacotherapy, or either intervention within 1 year following experiencing a PPF were determined. The rate of change for these interventions was calculated using the compounded annual growth rate (CAGR), with linear regression used to determine whether trends were statistically significant.</p><p><strong>Results: </strong>In total, 5.7% and 3.6% of patients were screened and treated for osteoporosis, respectively. Between 2010 and 2020, there was no significant change in rates of osteoporosis screening (CAGR + 0.1%; p = 0.13), treatment (CAGR - 2.4%; p = 0.29), or either intervention (CAGR - 1.1%; p = 0.77) within 1 year following PPF. Factors associated with intervention included older age, female sex, and increased comorbidities.</p><p><strong>Conclusion: </strong>Our study found that there has been no significant change in the rates of osteoporosis screening or treatment within 1 year following PPF. Orthopedic surgeons and allied healthcare workers can play an integral role in helping to curtail the osteoporosis epidemic.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"513-519"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users.","authors":"Yang-Chi Lin, Ping-Hao Chiang, Jing-Yang Huang, Wen-Shiann Wu","doi":"10.1007/s00198-024-07356-2","DOIUrl":"10.1007/s00198-024-07356-2","url":null,"abstract":"<p><p>This study examined the impact of thiazide and RAAS antihypertensive medications vs DHP-RAAS medications on fracture risk. The close alignment of such settings with clinical use, combined with the potential bone benefits of ACEis and ARBs, provides enhanced accuracy in bone health evidence.</p><p><strong>Purpose: </strong>To determine whether thiazides, combined with either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), offer bone-protective benefits compared with dihydropyridine (DHP) drugs combined with ACEi or ARB.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted on the US Collaborative Network from the TriNetX database on March 5th, 2024. It included hypertensive ACEi or ARB users under thiazide or DHP drug treatments spanning from January 1st, 2015, to December 31st, 2022, with exclusion criteria applied. The primary outcome is a composite typical osteoporotic fracture (TOPF). Kaplan Meier analyses were performed after 1:1 propensity-score matching (PSM) with a 5-year follow-up. Besides investigating fracture-related outcomes in thiazide-ACEi/ARB and DHP-ACEi/ARB users, this study explores whether the effects differ between ACEi and ARB users. Subgroup analyses were also performed, and the heterogeneity among the results was assessed using Cochran's Q-tests.</p><p><strong>Results: </strong>Post-PSM results yield 54,240 patients per cohort in the primary analysis, aging 61.5 ± 12.2 versus 61.4 ± 13.7 (thiazide-ACEi/ARB versus DHP-ACEi/ARB) with predominantly white ethnicity. Thiazide-ACEi/ARB users exhibit lower TOPF risk than DHP-ACEi/ARB users (hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.61-0.70), and such benefits from thiazides are similar between ACEi and ARB users (ACEi: HR = 0.69; ARB: HR = 0.67, Cochran's Q-test p-value = 0.78). Additionally, the effects of thiazides reveal significant heterogeneity between patients with and without inflammatory polyarthropathy (ICD-10, M05-M14) and benzodiazepine usage (Cochran's Q-test p-value = 0.01, 0.04).</p><p><strong>Conclusion: </strong>Thiazides are associated with lower risks of typical osteoporotic fractures compared to DHP drugs in patients treated with ACEi or ARB, while such benefits may diminish in those with a diagnosis of inflammatory polyarthropathy and benzodiazepine usage.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"411-422"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical trial landscape of anti-RANKL agents for osteoporosis: current status and future directions.","authors":"Xin Li, Lin Cheng","doi":"10.1007/s00198-025-07389-1","DOIUrl":"10.1007/s00198-025-07389-1","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"573-575"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}